Kashihara, Naoki
Yamasaki, Yoshimitsu
Osonoi, Takeshi
Harada, Hiromasa
Shibagaki, Yugo
Zhao, June
Kim, Hyosung
Yajima, Toshitaka
Sarai, Nobuaki http://orcid.org/0000-0002-7525-6102
Funding for this research was provided by:
AstraZeneca
Article History
Received: 12 May 2020
Accepted: 2 September 2020
First Online: 24 October 2020
Change Date: 28 January 2021
Change Type: Update
Change Details: The original version is updated due to missing of Electronic supplementary files
Compliance with ethical standards
:
: N Kashihara has received consulting fees from AstraZeneca, Gilead, Kyowa-Kirin, and GlaxoSmithKline, and has received honoraria for lectures from Daiichi-Sankyo, Takeda, Astellas, Otsuka, and Kyowa-Kirin, and has received research grants from Tanabe-Mitsubishi, Tore, Baxter, Cyugai-Seiyaku, Kyowa-Kirin, Bayer-Yakuhin, Ono-Yakuhin, Daiichi-Sankyo, Nihon-Boehringer Ingelheim, Astellas-Seiyaku, and Takeda-Yakuhin-Kogyo. J Zhao, H Kim, T Yajima, and N Sarai are employees of AstraZeneca. Y Yamasaki, T Osonoi, H Harada, and Y Shibagaki have no conflicts of interest to declare. This work was supported by AstraZeneca.
: All procedures performed in this study were approved by the institutional review board at each participating study site and were in compliance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.